Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099543 | 0.83 | NPC1 (0.36) | FFAR4HSD17B3GFERKDM4ELMNA | |
| SCHEMBL17099539 | 0.80 | HTT (0.42) | GAAMAPTALDH1A1HSPA9MEN1 | |
| SCHEMBL12036060 | 0.74 | FFAR4 (0.44) | GAAFFAR4MAPTKDM4EALDH1A1 | |
| SCHEMBL30350644 | 0.74 | FFAR4 (0.44) | GAAFFAR4MAPTKDM4EALDH1A1 | |
| SCHEMBL2306195 | 0.71 | NOTUM (0.43) | FSHRGAABRD4ATAD2HSD17B3 | |
| SCHEMBL22091235 | 0.71 | NR1H2 (0.47) | FSHRNR1H2BRD4ATAD2HSD17B3 | |
| SCHEMBL29963540 | 0.71 | BRD4 (0.51) | NR1H2BRD4ATAD2HSD17B3MAPT | |
| SCHEMBL2306434 | 0.71 | BRD4 (0.51) | NR1H2BRD4ATAD2HSD17B3MAPT | |
| SCHEMBL27612641 | 0.70 | NR1H2 (0.42) | NR1H2GAABRD4ATAD2HSD17B3 | |
| SCHEMBL27612686 | 0.69 | ALDH1A1 (0.43) | NR1H2GAABRD4ATAD2GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238198-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-08-05 | — | — | US | disclosed |
| US-10968236-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190248810-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-10253046-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshmi (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2016138352-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015143376-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238198-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | FSHR 2442/4885NR1H2 3260/4885GAA 1899/4885 |
| US-10968236-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | FSHR 2442/4885NR1H2 3260/4885GAA 1899/4885 |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | FSHR 2442/4885NR1H2 3260/4885GAA 1899/4885 |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | FSHR 2442/4885NR1H2 3260/4885GAA 1899/4885 |
| US-10253046-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | FSHR 2442/4885NR1H2 3260/4885GAA 1899/4885 |
| US-20190248810-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | FSHR 2442/4885NR1H2 3260/4885GAA 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.